Arecoline

Uses

Recreational

In many Asian cultures, the areca nut is chewed along with betel leaf to obtain a stimulating effect.

Medical

Arecoline has been used medicinally as an antihelmintic (a drug against parasitic worms). It paralyzes tapeworms.

Traditional medicine

Arecoline has been used in traditional medicine in Asia for thousands of years.

Toxicity

The of arecoline is 100 mg/kg, when administered subcutaneously in mice. The minimum lethal dose (MLD) values of arecoline in mice, dogs, and horses is 100 mg/kg, 5 mg/kg and 1.4 mg/kg respectively.

It causes oral submucous fibrosis by stimulating collagen, interleukin 6, keratinocyte growth factor-1, IGF-1, cystatin C, tissue inhibitor of matrix metalloproteinases in the mouth.

Current science is confident that areca nut chewing is carcinogenic. Research suggests this is probably at least partly because of arecoline itself, although it could also be from the other constituents of the nut as well, some of which are precursors to nitrosamines that form in the mouth during chewing. Section 5.5 Evaluation on page 238 of IARC Monograph 85-6 states the following:

The toxicity of arecoline can be partially mitigated by vitamins C and E in mice.

Mechanisms of toxicity

Arecoline is "obviously cytotoxic" to cultures of hepatocytes, bone marrow cells, lymphocytes, neuronal cell, myoblasts and endothelial cells.

Arecoline generates excessive reactive oxygen species (ROS) in a number of cell types, including oral epithelial cells and neuronal cells. In adult mice, arecoline is toxic to the testes and liver via ROS generation.

Arecoline is also genotoxic, being able to induce DNA damage and mutation in several cell cultures. Mice chronically exposed to arecoline show relaxation of their chromatin structure.

Pharmacology

Pharmacodynamics

Arecoline is the primary active ingredient responsible for the central nervous system effects of the areca nut. Arecoline has been compared to nicotine; however, nicotine agonizes nicotinic acetylcholine receptors, whereas arecoline is primarily a partial agonist of muscarinic acetylcholine receptors, leading to its parasympathetic effects. In frogs, arecoline also acts as an antagonist (or very weak partial agonist) at α4 and α6-containing nicotinic acetylcholine receptors and as a silent antagonist at α7 nicotinic receptors, which may account for its anti-inflammatory activity. Arecoline also inhibits AMPK through generation of ROS in several types of cells.

AN (Areca Nut) is a vasodilator mainly due to the presence of arecoline. It also has anti-thrombosis and anti-atherogenic effects by increasing plasma nitric oxide, eNos, and mRNA expression and decreasing IL-8 along with other downregulations. It increases the level of testosterone by stimulating Leydig's cells as well as levels of FSH and LH. It also activates HPA axis and stimulates CRH release. It prevents the dysfunction of B cells of the pancreas from high fructose intake. Arecoline has the ability to stimulate the digestive system through the activation of muscarinic receptors. Areca nut water extract could increase the contractions of gastric smooth muscle and muscle strips of the duodenum, ileum, and colon significantly. This activity could be caused by arecoline.

Pharmacokinetics

Arecoline is metabolized by both kidneys and liver. Currently, 11 metabolites of arecoline are documented among which N-methylnipecotic acid was found to be a major metabolite of both arecoline and arecaidine. Lime, which is traditionally mixed to crushed areca nuts prior to consumption, is said to hydrolyse almost all arecoline to arecaidine, a GABA reuptake inhibitor. Arecaidine is also formed during liver metabolism of arecoline in rats.

Arecoline is very efficiently absorbed through oral musoca, with 85% bioavailbility. Maximum plasma concentration is reached within 3 minutes.

Orally ingested arecoline is extensively metabolized in rats, with the vast majority of the dose being converted to arecaidine and arecoline N-oxide.

Chemistry

Arecoline is a colorless odorless oily liquid. It is a base, and its conjugate acid has a pKa ~ 6.8. Arecoline is volatile in steam, miscible with most organic solvents and water, but extractable from water by ether in presence of dissolved salts. Being basic, arecoline forms salts with acids. The salts are crystalline, but usually deliquescent: the hydrochloride, arecoline•HCl, forms needles, m.p. 158 °C; the hydrobromide, arecoline•HBr, forms slender prisms, mp. 177–179 °C from hot methanol; the aurichloride, arecoline•HAuCl4, is an oil, but the platinichloride, arecoline2•H2PtCl6, mp. 176 °C, crystallizes from water in orange-red rhombohedrons. The methiodide forms glancing prisms, mp. 173–174 °C.

Synthesis

The double Michael reaction between methyl acrylate [96-33-3] (1) and aqueous methylamine (2) gave N,N-Bis(-methoxycarbonylethyl)methylamine [105-71-5] (3). Dieckmann cyclization led to 1-Methyl-3-carbomethoxy-4-piperidone [13221-89-1] (4). The reduction of the ketone group with sodium borohydride gave N-Methyl-3-carbomethoxy-4-hydroxypiperidine, PC3029557 (5). Reaction with methanesulfonyl chloride followed by addition of hydrobromic acid completed the synthesis of arecoline hydrobromide (6). N.B. compound #4 is similar to a compound used in the synthesis of GSK1360707F.

Fischer esterification of nicotinic acid (niacin) (1) gives methyl nicotinate (2). Alkylation with methyl iodide then gives 3-methoxycarbonyl-1-methylpyridinium iodide (3). Hydride reduction with an agent such as potassium borohydride thus gives the tetrahydropyridine (4). Salt formation with HBr completes the synthesis (5).

A double Mannich reaction between methylamine (1), acetaldehyde (2) and formaldehyde (3) in the presence of hydroxylamine hydrochloride is supposed to have delivered 1-methyl-1,2,5,6-tetrahydropyridine-3-carbaldehyde oxime hydrochloride (4) as the product. Dehydration of the aldoxime to the nitrile occurs upon treatment with acetic anhydride giving 3-cyano-1-methyl-1,2,5,6-tetrahydropyridine (5). Functional group interconversion of the nitrile to the methyl carboxylate ester then occurs upon acid-catalyzed treatment in methanol, and then conversion to the HBr salt completes the synthesis. N.B. Although the first step is not very high yielding, if one substitutes methoxyamine for hydroxylamine procedure could be used for a one-pot synthesis of milameline.

Chemical precursor

Arecoline is used in the synthesis of a variety of other drugs, including paroxetine, femoxetine, nocaine, DMNPC, piquindone, PC10058081 (epiboxidine type), FT-0731096 [114724-56-0], piper-brasofensine piper-Tesofensine and BRN 0023391 [102206-67-7].

Analogues

Analogues of and related compounds to arecoline include arecaidine, guavacoline, guvacine, nipecotic acid, nicotinic acid, muscarine, SKF-89976A, tiagabine, and CI-966. Xanomeline, the anti-schizophrenia component in the approved drug xanomeline/trospium chloride, also has structural similarities to arecoline.

Research

Owing to its muscarinic and nicotinic agonist properties, arecoline has shown improvement in the learning ability of healthy volunteers. Since one of the hallmarks of Alzheimer's disease is a cognitive decline, arecoline was suggested as a treatment to slow down this process. Arecoline administered intravenously did indeed show modest verbal and spatial memory improvement in Alzheimer's patients, though due to arecoline's possible carcinogenic properties (see ), it is not the first drug of choice for this degenerative disease.

Anecdotal reports indicate that it has a short-lived effect against schizophrenia. Among male schizophrenia patients, higher areca nut consumption is associated with weaker symptoms. It inspired the development of xanomeline.

Veterinary use

In 2012, Chinese Ministry of Agriculture listed arecoline hydrobromide as an abolished veterinary drug and stopped its production and use.

References

References

1. (30 September 2020). "Poisons Standard October 2020". The Australian Government.
2. (May 2019). "DARK Classics in Chemical Neuroscience: Arecoline". ACS Chemical Neuroscience.
3. (September 2022). "Betel quid: New insights into an ancient addiction". Addict Biol.
4. (1981). "Discriminative stimulus properties of arecoline: a new approach for studying central muscarinic receptors". Psychopharmacology (Berl).
5. (May 2019). "Cracking the Betel Nut: Cholinergic Activity of Areca Alkaloids and Related Compounds". Nicotine Tob Res.
6. (October 2017). "Intoxication and substance use disorder to Areca catechu nut containing betel quid: A review of epidemiological evidence, pharmacological basis and social factors influencing quitting strategies". Drug Alcohol Depend.
7. (July 2004). "Epidemiology of betel quid usage". Annals of the Academy of Medicine, Singapore.
8. (July 2002). "Oral submucous fibrosis in a 12-year-old Bangladeshi boy: a case report and review of literature". International Journal of Paediatric Dentistry.
9. International Agency for Research on Cancer. (2005). "Betel-quid and areca-nut chewing. IARC Monograph 85-6". IARC.
10. (April 2014). "The hepatotoxicity and testicular toxicity induced by arecoline in mice and protective effects of vitamins C and e". The Korean Journal of Physiology & Pharmacology.
11. (May 1999). "Arecoline-induced changes of poly-ADP-ribosylation of cellular proteins and its influence on chromatin organization". Cancer Letters.
12. (July 1987). "Differential receptor occupancy requirements for muscarinic cholinergic stimulation of inositol lipid hydrolysis in brain and in neuroblastomas". Molecular Pharmacology.
13. (February 1991). "Pharmacologic comparison of selected agonists for the M1 muscarinic receptor in transfected murine fibroblast cells (B82)". The Journal of Pharmacology and Experimental Therapeutics.
14. (2015). "Nicotinic Activity of Arecoline, the Psychoactive Element of "Betel Nuts", Suggests a Basis for Habitual Use and Anti-Inflammatory Activity". PLOS ONE.
15. (May 2011). "Arecoline-mediated inhibition of AMP-activated protein kinase through reactive oxygen species is required for apoptosis induction". Oral Oncology.
16. (August 2008). "Effects of arecoline on testosterone release in rats". American Journal of Physiology. Endocrinology and Metabolism.
17. (2015). "A protective role of arecoline hydrobromide in experimentally induced male diabetic rats". BioMed Research International.
18. (January 2016). "Neuropathology of Drug Addictions and Substance Misuse; Volume 3: General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-Drug Addictions". Academic Press.
19. (June 2006). "A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse". Chemical Research in Toxicology.
20. (December 1975). "Betel nut constituents as inhibitors of gamma-aminobutyric acid uptake". Nature.
21. (2016). "Neuropathology of Drug Addictions and Substance Misuse".
22. (May 2018). "Development and validation of a rapid LC-MS/MS method for simultaneous quantification of arecoline and its two active metabolites in rat plasma and its application to a pharmacokinetic study". Journal of Pharmaceutical and Biomedical Analysis.
23. (1983). "The Merck index: an encyclopedia of chemicals, drugs, and biologicals". Merck & Co..
24. 钱莉苹, 吴世刚, & 黄勇, CN118812418 (2024 to Yifan Pharmaceutical Shanghai Co ltd, Hefei Yifan Biological Pharmaceutical Co ltd).
25. {{cite patent. link
26. Levy Joseph, US2569182 (1951 to Nopco Chemical Co).
27. (November 1976). "Improvement of the synthesis of arecoline from nicotinic acid.". Pharmaceutical Chemistry Journal.
28. {{cite patent. link
29. (November 1979). "An improved method of preparation of arecoline, starting from acetaldehyde (exchange of experience).". Pharmaceutical Chemistry Journal.
30. Ward; Neal, Process for making paroxetine, {{US patent. 6172233, 2001.
31. Ward Neal, process of the preparation of 3-substituted-4-aryl piperidine compounds, WO 0232870, 2002.
32. Coffen, David L.; Hengartner, Urs; Katonak, David A.; Mulligan, Mary E.; Burdick, David C.; Olson, Gary L.; Todaro, Louis J. (1984). "Syntheses of an antipsychotic pyrrolo[2,3-g]isoquinoline from areca alkaloids". The Journal of Organic Chemistry 49 (26): 5109–5113. doi:10.1021/jo00200a019.
33. Peter Moldt, Frank Watjen, & Jorgen Scheel-Kruger, WO1998051668 (to NTG Nordic Transport Group AS).
34. Frank Wätjen, et al. WO2004039778 (to NTG Nordic Transport Group AS).
35. (September 2022). "Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia". The American Journal of Psychiatry.
36. (November 2016). "The pharmacology, toxicology and potential applications of arecoline: a review". Pharmaceutical Biology.
37. (2012-11-20). "中华人民共和国农业部公告 第1845号".